Clinical trial
An Open-label, Roll-over Study Evaluating the Long-term Safety and Efficacy of an Oral Dose of Verducatib q.d. in Patients With Bronchiectasis (AIRTIVITY®-ON)
NCT07915219 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-label, Roll-over Study Evaluating the Long-term Safety and Efficacy of an Oral Dose of Verducatib q.d. in Patients With Bronchiectasis (AIRTIVITY®-ON)
- Lead sponsor
- Boehringer Ingelheim
- Phase
- Phase 3
- Overall status
- Not yet recruiting
- Start date
- January 11, 2027
- Completion date
- September 10, 2029
- Enrollment
- 1,500 (estimated)
- Sites
- 394
Conditions
As the registry lists them; a condition with its own page is linked.
Arms
As registered; 1 arm.
-
Participants with bronchiectasis rolling over from parent trials
Participants with bronchiectasis who completed parent trials AIRTIVITY® (1397-0014) or CLAIRLEAF® (1397-0017) and did not prematurely discontinue the trial drug.
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Occurrence of treatment-emergent adverse events (TEAEs) over the course of this trial
Lead sponsor's other trials
Boehringer Ingelheim, most recent start first.
+2,298 more trials See the organization page
Similar trials
Same condition (Bronchiectasis) and phase, most recent start first.
+21 more trials See the condition page